GlassScriptPhysician profile
Meghan A Reddick
NPI 1184103129
$1,901.33
in general payments reported to CMS, 2019-2025
24 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $673 · 2023: $920 · 2024: $67.97 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,072 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,072.14 |
| Education | $155.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $323.20 | 2023-2025 | Darzalex, Rybrevant, Carvykti |
| Amgen INC. | $219.20 | 2022-2023 | Kyprolis, Lumakras, Blincyto |
| Genzyme Corporation | $205.81 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $155.41 | 2022-2023 | Libtayo |
| Jazz Pharmaceuticals INC. | $143.71 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $126.74 | 2023-2024 | Opdivo |
| Mirati Therapeutics, INC. | $113.36 | 2023 | Krazati |
| Genentech USA, INC. | $102.85 | 2022-2023 | Venclexta, Lunsumio, Polivy |
| Caris Mpi, INC. | $95.38 | 2025 | Mi Cancer Seek |
| Lilly USA, LLC | $65.81 | 2022-2023 | Taltz, Olumiant |
| Celgene Corporation | $52.14 | 2022-2023 | Reblozyl |
| Gilead Sciences, INC. | $46.99 | 2022-2023 | Trodelvy |
| G1 Therapeutics, INC. | $33.42 | 2022-2023 | Cosela |
| Sumitomo Pharma America, INC. | $31.62 | 2023 | Orgovyx |
| Seagen INC. | $23.01 | 2023 | Padcev |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $22.97 | 2023 | |
| Glaxosmithkline, LLC. | $22.09 | 2022 | |
| Merck Sharp & Dohme LLC | $21.50 | 2023 | Keytruda |
| Daiichi Sankyo INC. | $19.25 | 2022 | |
| Pharmaessentia USA Corporation | $19.23 | 2023 | Besremi |
| Abbvie INC. | $17.08 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $13.92 | 2022 | |
| Pfizer INC. | $13.73 | 2023 | |
| Kyowa Kirin, INC. | $12.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghan Reddick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.